turmetabart adizutecan (ABBV-706) / AbbVie - LARVOL DELTA

Efficacy and Safety of ABBV-706 Versus Standard of Care in Relapsed/Refractory Small Cell Lung Cancer: A Phase 3 Study (IASLC-WCLC 2026) - P1, P3 | "Tarlatamab, a recommended standard of care (SOC) in second line (2L) for patients with ES-SCLC with disease progression on or after platinum-based chemotherapy, offers improved response rates in heavily treated relapsed/refractory (R/R) patients; however, treatment options in this setting are still limited...Methods : M23-384 (NCT07365241) is a Phase 3, global, randomized, open-label, multicenter (~175 sites) study, evaluating the safety and efficacy of ABBV-706 versus SOC (topotecan, lurbinectedin, or amrubicin) in patients with R/R SCLC...Key secondary endpoints include progression-free survival and duration of response based on BICR assessment per RECIST v1.1, patient-reported outcomes (change from baseline at Week 12 in physical functioning as measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [EORTC QLQ-C30], and in Global Health Status [GHS]/QoL as measured by the EORTC QLQ-C30 GHS/QoL scale), and..."

Clinical • First-in-human • P3 data • CNS Disorders • Epilepsy • Interstitial Lung Disease • Lung Cancer • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • SEZ6

ABBV-706: A First-in-Class SEZ6-Targeted Topoisomerase 1 Inhibitor (Top1i)-Antibody-Drug Conjugate (ADC) With Robust Antitumour Activity in Relapsed/Refractory Small Cell Lung Cancer (R/R SCLC) (ESMO 2026) - No abstract available

ADC • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • SEZ6

First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. (ASCO 2024) - P1 | " Phase 1, open-label, multicenter, DE and dose-expansion study (NCT05599984) of ABBV-706 as monotherapy or in combination with budigalimab (a programmed cell death 1 inhibitor), carboplatin, or cisplatin. ABBV-706 demonstrated a manageable safety profile with promising efficacy in SCLC and NENs. Further evaluation of ABBV-706 is ongoing."

Clinical • Metastases • P1 data • Anemia • Brain Cancer • CNS Disorders • CNS Tumor • Endocrine Cancer • Epilepsy • Fatigue • Gastrointestinal Disorder • Glioma • Hematological Disorders • Interstitial Lung Disease • Leukopenia • Lung Cancer • Neuroendocrine Tumor • Neutropenia • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia • SEZ6

ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC). (ASCO 2026) - P1 | "ABBV-706 monotherapy shows promising OS benefit in a heavily pretreated pt population with R/R SCLC and is combinable with a CPI. Efficacy of ABBV-706 in R/R SCLC. aConfirmed by investigator per RECIST v1.1."

Clinical • Combination therapy • Monotherapy • CNS Disorders • Epilepsy • Lung Cancer • Oncology • Pneumonia • Small Cell Lung Cancer • Solid Tumor • SEZ6

Hematologic and Gastrointestinal Toxicity of ABBV-706 in Advanced Solid Tumors: Safety Profile From the First-in-Human Study (IASLC-WCLC 2026) - P1 | "Other common TRAEs were fatigue (37.9%) and decreased appetite (20.8%), with fatigue being the most common non-hematologic, non-gastrointestinal G3+ TRAE (3.8%). Conclusions : ABBV-706 demonstrated an acceptable safety profile with frequent but manageable cytopenia and low-grade gastrointestinal toxicity."

Clinical • First-in-human • Metastases • P1 data • Brain Cancer • CNS Disorders • CNS Tumor • Endocrine Cancer • Epilepsy • Febrile Neutropenia • Interstitial Lung Disease • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Neutropenia • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • SEZ6

Safety and Efficacy of ABBV-706, a Seizure-related Homolog Protein 6-targeting Antibody-drug Conjugate, in R/R SCLC (IASLC-WCLC 2025) - P1 | "ABBV-706 has manageable safety and promising efficacy in patients with R/R SCLC. Based on the totality of the benefit-risk profile, monotherapy RP2D was determined to be 1.8 mg/kg Q3W in SCLC."

Clinical • Anemia • CNS Disorders • Epilepsy • Fatigue • Interstitial Lung Disease • Lung Cancer • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • SEZ6

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. (PubMed, Nat Med) - P1 | "Based on the totality of available data, including, but not limited to, safety, preliminary efficacy measures and PK, 1.8 mg kg-1 Q3W was confirmed as the optimal RP2D for patients with R/R SCLC. ClinicalTrials.gov: NCT05599984 ."

Journal • P1 data • Brain Cancer • CNS Disorders • CNS Tumor • Endocrine Cancer • Epilepsy • Fatigue • Hematological Disorders • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • SEZ6

Pneumonitis/Interstitial Lung Disease in the First-in-Human ABBV-706 Study: Incidence, Management, and Risk Factors (IASLC-WCLC 2026) - P1 | "Prior PD-L1 therapy and prior thoracic radiation were present in 7 and 1 adjudicated pneumonitis/ILD cases, respectively. Conclusions : High-grade pneumonitis/ILD events were reported, highlighting the need for careful monitoring and adherence to management guidelines; however, the adjudicated treatment-emergent pneumonitis/ILD rate seen with ABBV-706 monotherapy was low (4.2%)."

Clinical • First-in-human • P1 data • Brain Cancer • CNS Disorders • CNS Tumor • Endocrine Cancer • Epilepsy • Infectious Disease • Inflammation • Interstitial Lung Disease • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Pneumonia • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • SEZ6

Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms. (ASCO 2025) - P1 | "ABBV-706 showed preliminary efficacy in several high-grade NENs with a high unmet need, supporting its further development in specific subtypes."

Clinical • Anemia • CNS Disorders • Endocrine Cancer • Epilepsy • Fatigue • Genito-urinary Cancer • Interstitial Lung Disease • Lung Cancer • Neuroendocrine Tumor • Neutropenia • Oncology • Pneumonia • Prostate Cancer • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • SEZ6

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline (AbbVie Press Release) - "Additionally, new data and updates from AbbVie's telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across NSCLC and small cell lung cancer (SCLC) to be shared."

Clinical data • Non Small Cell Lung Cancer • Small Cell Lung Cancer

Phase 1, first-in-human (FIH) study evaluating safety and efficacy of ABBV-706: Results from patients with high-grade central nervous system (CNS) tumors. (ASCO 2026) - P1 | "In pts with previously treated primary CNS tumors, ABBV-706 had a comparable safety profile to that observed in other tumors and showed encouraging antitumor activity. Efficacy of ABBV-706.a aBy investigator per RANO. bIncluding confirmed + preliminary."

Clinical • First-in-human • P1 data • Astrocytoma • Brain Cancer • CNS Disorders • CNS Tumor • Epilepsy • Glioblastoma • Lung Cancer • Oncology • Pneumonia • Small Cell Lung Cancer • SEZ6

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=531 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: AbbVie | Trial completion date: Sep 2031 ➔ May 2029

Adverse events • Trial completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: AbbVie | N=50 ➔ 180

Adverse events • Enrollment change • Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=730 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P2/3 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=180 | Not yet recruiting | Sponsor: AbbVie | N=730 ➔ 180 | Trial completion date: Sep 2031 ➔ May 2029 | Trial primary completion date: Sep 2031 ➔ May 2029

Adverse events • Enrollment change • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: AbbVie | N=27 ➔ 180

Adverse events • Enrollment change • Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: AbbVie | N=60 ➔ 180

Adverse events • Enrollment change • Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Decoding Small Cell Lung Cancer: Molecular Subtypes, Surface Antigens, and the Target-Modality Problem. (PubMed, Cancers (Basel)) - "Second, the development of delta-like ligand 3 (DLL3)-directed therapies provides a natural experiment: the same validated surface antigen failed as an antibody-drug conjugate (rovalpituzumab tesirine, three negative randomized trials) yet succeeded as a bispecific T-cell engager (tarlatamab, which received FDA accelerated approval in 2024 and subsequent traditional FDA approval in 2025 following positive confirmatory phase 3 data). In this review, we integrate the current first-line standard of care-chemoimmunotherapy with atezolizumab- or durvalumab-based regimens followed by maintenance intensification with lurbinectedin-atezolizumab (IMforte)-with the molecular framework of subtypes and biomarkers, and we use DLL3 as a case study to propose that delivery modality is an important determinant of therapeutic success in SCLC and should be considered alongside target biology and tumor heterogeneity...The emerging B7-H3 and SEZ6 programs-including ifinatamab deruxtecan and..."

IO biomarker • Journal • Review • CNS Disorders • Lung Cancer • Oncology • Psychiatry • Small Cell Lung Cancer • Solid Tumor • ASCL1 • CD276 • DLL3 • NEUROD1 • POU2F3 • RB1 • SEZ6 • TP53

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: AbbVie | N=27 ➔ 50

Adverse events • Enrollment change • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: AbbVie | Trial completion date: May 2029 ➔ Sep 2031

Adverse events • Trial completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2/3 | N=180 | Not yet recruiting | Sponsor: AbbVie | Trial completion date: May 2029 ➔ Sep 2031

Adverse events • Trial completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting | Phase classification: P2/3 ➔ P2

Adverse events • Enrollment open • Phase classification • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=27 | Recruiting | Sponsor: AbbVie

Adverse events • New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC). (ASCO 2026) - P2 | "Adding a PD-L1 inhibitor (atezo or durvalumab) to PCT only modestly improves survival, and novel therapies are needed...SOC includes 4 cycles of PCT (carboplatin) + etoposide + atezo followed by atezo maintenance; lurbinectedin may also be used in maintenance where locally approved...Treatment continues until progression, intolerable toxicity, or other discontinuation criteria are met. The study is enrolling."

Clinical • Combination therapy • IO biomarker • P2 data • CNS Disorders • Epilepsy • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • SEZ6